A Study to Evaluate the Bioavailability of Risankizumab in Pre-filled Syringe or Auto-injector in Healthy Adult Participants
Part of paid clinical trials in Grayslake, Illinois.
- Sponsor
- AbbVie
- Study ID
- NCT05283681
- Phase
- PHASE1
- Status
- Completed
Conditions
- Healthy Volunteers
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 55 Years
- Healthy Volunteers
- Accepted
Interventions
- Risankizumab — DRUGSubcutaneous Injection via Prefilled Syringe (PFS)
- Risankizumab — DRUGSubcutaneous Injection via Auto-Injector (AI)
Study Details
The objective of this study is to evaluate the bioavailability of risankizumab new formulation in prefilled syringe (PFS) relative to the 90 mg/mL formulation in PFS in healthy volunteers. The study will also evaluate the bioavailability of risankizumab new formulation in auto-injector (AI) relative to PFS in healthy volunteers.
Key Dates
- Start date
- Apr 2, 2019
- Status verified
- Mar 2022
- Primary completion
- Nov 11, 2019
- Completion
- Nov 11, 2019
Study Design
- Enrollment
- 226 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- BASIC_SCIENCE
Arms
- Experimental: Risankizumab Dose AParticipants will receive 1 Subcutaneous (SC) injection of risankizumab Dose A administered via Prefilled Syringe (PFS) at Day 1 and followed for 140 days
- Experimental: Risankizumab Dose BParticipants will receive SC injections of risankizumab Dose B administered via PFS at Day 1 and followed for 140 days
- Experimental: Risankizumab Dose CParticipants will receive 1 SC injection of risankizumab Dose C administered via Auto-Injector (AI) at Day 1 and followed for 140 days.
Primary Outcome Measure
Number of Participants with Adverse Events [ Time Frame: Up to 140 Days ]
Locations (2)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Acpru /Id# 210844 | Grayslake | Illinois | 60030 | - |
| PPD Clinical Research Unit - Austin /ID# 211456 | Austin | Texas | 78744 | - |
Find similar trials in Grayslake, IL
Related Studies
- A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)PHASE1/PHASE2 · Recruiting · Regeneron Pharmaceuticals · Glendale, California
- A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell DiseasePHASE1/PHASE2 · Recruiting · Bristol-Myers Squibb · Birmingham, Alabama
- A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MKND-201 in Healthy VolunteersPHASE1 · Recruiting · Mannkind Corporation · San Antonio, Texas
- Blood Flow Restriction (BFR) Training on the Ulnar Collateral Ligament (UCL)Recruiting · The Methodist Hospital Research Institute · Houston, Texas